Study Protocol of Expanded Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro-EXP)
- Author:
Jae Hoon MOON
1
;
Eun Kyung LEE
;
Wonjae CHA
;
Young Jun CHAI
;
Sun Wook CHO
;
June Young CHOI
;
Sung Yong CHOI
;
A Jung CHU
;
Eun-Jae CHUNG
;
Yul HWANGBO
;
Woo-Jin JEONG
;
Yuh-Seog JUNG
;
Kyungsik KIM
;
Min Joo KIM
;
Su-jin KIM
;
Woochul KIM
;
Yoo Hyung KIM
;
Chang Yoon LEE
;
Ji Ye LEE
;
Kyu Eun LEE
;
Young Ki LEE
;
Hunjong LIM
;
Do Joon PARK
;
Sue K. PARK
;
Chang Hwan RYU
;
Junsun RYU
;
Jungirl SEOK
;
Young Shin SONG
;
Ka Hee YI
;
Hyeong Won YU
;
Eleanor WHITE
;
Katerina MASTROCOSTAS
;
Roderick J. CLIFTON-BLIGH
;
Anthony GLOVER
;
Matti L. GILD
;
Ji-hoon KIM
;
Young Joo PARK
Author Information
- Publication Type:Original Article
- From:Endocrinology and Metabolism 2025;40(2):236-246
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:Active surveillance (AS) has emerged as a viable management strategy for low-risk papillary thyroid microcarcinoma (PTMC), following pioneering trials at Kuma Hospital and the Cancer Institute Hospital in Japan. Numerous prospective cohort studies have since validated AS as a management option for low-risk PTMC, leading to its inclusion in thyroid cancer guidelines across various countries. From 2016 to 2020, the Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro) enrolled 1,177 patients, providing comprehensive data on PTMC progression, sonographic predictors of progression, quality of life, surgical outcomes, and cost-effectiveness when comparing AS to immediate surgery. The second phase of MAeSTro (MAeSTro-EXP) expands AS to low-risk papillary thyroid carcinoma (PTC) tumors larger than 1 cm, driven by the hypothesis that overall risk assessment outweighs absolute tumor size in surgical decision-making.
Methods:This protocol aims to address whether limiting AS to tumors smaller than 1 cm may result in unnecessary surgeries for low-risk PTCs detected during their rapid initial growth phase. By expanding the AS criteria to include tumors up to 1.5 cm, while simultaneously refining and standardizing the criteria for risk assessment and disease progression, we aim to minimize overtreatment and maintain rigorous monitoring to improve patient outcomes.
Conclusion:This study will contribute to optimizing AS guidelines and enhance our understanding of the natural course and appropriate management of low-risk PTCs. Additionally, MAeSTro-EXP involves a multinational collaboration between South Korea and Australia. This cross-country study aims to identify cultural and racial differences in the management of low-risk PTC, thereby enriching the global understanding of AS practices and their applicability across diverse populations.
